UY26731A1 - Combinación de secretagogos de hormona del crecimiento y antidepresivos - Google Patents

Combinación de secretagogos de hormona del crecimiento y antidepresivos

Info

Publication number
UY26731A1
UY26731A1 UY26731A UY26731A UY26731A1 UY 26731 A1 UY26731 A1 UY 26731A1 UY 26731 A UY26731 A UY 26731A UY 26731 A UY26731 A UY 26731A UY 26731 A1 UY26731 A1 UY 26731A1
Authority
UY
Uruguay
Prior art keywords
prodrug
growth hormone
antidepressants
secretagogos
combination
Prior art date
Application number
UY26731A
Other languages
English (en)
Inventor
Frank Robert Busch
Willard Mckowan Welch Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26731A1 publication Critical patent/UY26731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinaciones comprendiendo un secretagogo de hormona del crecimiento, un profármaco de éste o una sal farmacéuticamente aceptable del secretagogo de la hormona de crecimiento o del citado profármaco y un antidepresivo, un profármaco de éste o una sal farmacéuticamente aceptable del citado antidepresivo o del citado profármaco y a composiciones farmacéuticas y estuches comprendiendo dichas combinaciones. Los antidepresivos dentro de esta invención incluyen inhibidores de la recaptación de norepinefrina (por ejemplo compuestos tricíclicos con amina secundaria o terciaria), inhibidores selectivos de la recaptación de sertralina, agentes inhibidores de la recaptación de norepinefrina/sertralina combinados, inhibidores de monoaminooxidasa y antidepresivos atípicos.
UY26731A 2000-05-25 2001-05-25 Combinación de secretagogos de hormona del crecimiento y antidepresivos UY26731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20701700P 2000-05-25 2000-05-25

Publications (1)

Publication Number Publication Date
UY26731A1 true UY26731A1 (es) 2001-12-28

Family

ID=22768871

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26731A UY26731A1 (es) 2000-05-25 2001-05-25 Combinación de secretagogos de hormona del crecimiento y antidepresivos

Country Status (17)

Country Link
US (1) US20020002137A1 (es)
EP (1) EP1284753A2 (es)
JP (1) JP2003534294A (es)
AR (1) AR028620A1 (es)
AU (1) AU2001255013A1 (es)
BR (1) BR0111002A (es)
CA (1) CA2408036A1 (es)
DO (1) DOP2001000154A (es)
EC (1) ECSP014082A (es)
GT (1) GT200100089A (es)
MX (1) MXPA02011554A (es)
PA (1) PA8517701A1 (es)
PE (1) PE20011262A1 (es)
SV (1) SV2001000465A (es)
TN (1) TNSN01076A1 (es)
UY (1) UY26731A1 (es)
WO (1) WO2001089570A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
WO2005021555A1 (ja) * 2003-08-29 2005-03-10 Takeda Pharmaceutical Company Limited 二環性ピペラジン化合物およびその用途
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
EP2727915B1 (en) 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
WO2022087011A1 (en) 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP1001970B1 (en) * 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Also Published As

Publication number Publication date
PE20011262A1 (es) 2001-12-11
JP2003534294A (ja) 2003-11-18
WO2001089570A3 (en) 2002-06-20
GT200100089A (es) 2002-01-11
WO2001089570A2 (en) 2001-11-29
AR028620A1 (es) 2003-05-14
EP1284753A2 (en) 2003-02-26
MXPA02011554A (es) 2003-04-25
CA2408036A1 (en) 2001-11-29
ECSP014082A (es) 2002-04-23
BR0111002A (pt) 2003-04-15
TNSN01076A1 (fr) 2005-11-10
DOP2001000154A (es) 2002-05-15
PA8517701A1 (es) 2002-12-30
US20020002137A1 (en) 2002-01-03
SV2001000465A (es) 2001-07-03
AU2001255013A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
UY26731A1 (es) Combinación de secretagogos de hormona del crecimiento y antidepresivos
AR024159A1 (es) Nuevo uso de compuestos como agentes antibacterianos
MY117971A (en) Denaturants for sympathomimetic amine salts
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
HN2002000030A (es) Nueva sal succinato de o-desmetil-venlafaxina
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
UY28348A1 (es) Compuestos novedosos
DK1653947T3 (da) (Hydroxyphenyl)-1H-indol-3-carbaldehydoximderivater som östrogenmidler
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
EA200200916A1 (ru) Производные дифениловых эфиров, используемых в терапии
PA8582201A1 (es) Indoles 2,7-sustituidos
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
PA8461901A1 (es) Nuevo procedimiento para preparar una cetoimina
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140129